Promising insights with non-invasive MRI as biomarkers in Chronic Kidney Disease at ERA/EDTA 2019

Antaros Medical, in collaboration with Sahlgrenska University Hospital and AstraZeneca, are presenting new promising data during the 56th ERA-EDTA congress taking place in Budapest, June 13-16, 2019. Three posters are presented showing different aspects of magnetic resonance imaging (MRI) as a non-invasive tool that increases precision, sensitivity and repeatability for drug development in chronic kidney disease (CKD).

FP491:

Magnetic Resonance Imaging allows a novel non-invasive functional and pathophysiologic assessment of diabetic kidney disease

Presenter: Adjunct Professor Paul Hockings, Antaros Medical

Authors: Kianoush Makvandi, Gert Jensen, Paul Hockings, Tim Unnerstall, Henrik Leonhardt, Lisa Jarl, Anna Frödén Löwenmark, Camilla Englund, Susan Francis, Fredrik Erlandsson, Anna K Sundgren, Johannes Hulthe, Seema Baid-Agrawal

FP512:

MR imaging biomarkers of Diabetic Kidney Disease

Presenter: Adjunct Professor Paul Hockings, Antaros Medical

Author: Paul Hockings, Kianoush Makvandi, Tim Unnerstall, Henrik Leonhardt, Anna Frödén Löwenmark , Lisa Jarl, Camilla Englund, Susan Francis, Gert Jensen, Fredrik Erlandsson, Anna K Sundgren, Johannes Hulthe, Seema Baid-Agrawal

FP494:

Magnetic Resonance Imagining Biomarkers correlate to UACR in Diabetic Kidney Disease

Presenter:

Author: Kianoush Makvandi, Gert Jensen, Paul Hockings, Tim Unnerstall, Henrik Leonhardt, Lisa Jarl, Anna Frödén Löwenmark, Camilla Englund, Susan Francis, Fredrik Erlandsson, Anna K Sundgren, Johannes Hulthe, Seema Baid-Agrawal

Pressify Share on Linkedin Share on Twitter